

Copyright 2014 SLACK Inc.

The Efficacy of Transcranial Magnetic Stimulation for Major Depression: A Review of the Evidence

Philip G. Janicak, MD; and Linda Carpenter, MD

ABSTRACT

Major depression is a leading cause of disease burden worldwide. Although various treatment approaches exist, including pharmacological (eg, antidepressant agents), psychotherapeutic (eg, cognitive-behavioral therapy), and neuromodulatory (eg, electroconvulsive therapy [ECT]), a substantial number of patients do not adequately benefit from or cannot tolerate these existing options. This has led to a re-emergence of other neurostimulation

strategies, the best studied to date being transcranial magnetic stimulation (TMS). This article reviews the rationale for TMS in treating depression with a brief description of the basic principles underlying magnetic stimulation; a discussion of its putative mechanism of action; and its recommended treatment parameters. We then focus on the evidence base to support its use as both a monotherapy and adjunctive therapy for the acute and maintenance treatment of major depression. These data

came from controlled trials comparing TMS to a sham procedure and naturalistic outcome studies for acute depression; studies directly comparing TMS to ECT for major depression; and open-label studies, retrospective analyses, naturalistic outcome studies, and case reports that consider the durability of TMS' effect after acute response. The results of these studies have led to a growing use of TMS in clinical practice for treatment-resistant depression. [*Psychiatr Ann.* 2014; 44(6):284–292.]

Philip G. Janicak, MD, is Professor of Psychiatry, and Director, Transcranial Magnetic Stimulation Center, Rush University Medical Center. Linda Carpenter, MD, is Professor, Brown Department of Psychiatry and Human Behavior, and Chief, Butler Hospital Mood Disorders Program.

Address correspondence to: Philip G. Janicak, MD, Rush University Medical Center, Psychiatric Clinical Research Center, 2150 West Harrison Street, Suite 253, Chicago, IL 60612; email: pjanicak@rush.edu.

Disclosure: Dr. Janicak serves as a consultant for Neuronetics and conducts research for Cerevel Neurotech, Inc., Neuronetics, Johnson & Johnson, Otsuka, and Sunovion. Dr. Carpenter serves as consultant for Magstim, Naurex, Takeda/Lundbeck, AbbVie, and Taisho and conducts research for Neuronetics, NeoSync, and Cerevel Neurotech, Inc.

doi:10.3928/00485713-20140609-06



Copyright 2014 SLACK Inc.

Major depressive disorder (MDD) is reaching unprecedented levels worldwide and is identified as a leading cause of disease burden and higher health care utilization.^{1,2} Further, estimates of insufficient response and/or intolerability to standard antidepressant medications are in the 30% to 50% range.³ The need for more effective, alternative treatments with improved safety and tolerability profiles is clear. One such approach involves repetitive transcranial magnetic stimulation (rTMS, or simply “TMS”). In this review, we briefly consider the basic principles of TMS, its putative mechanism of therapeutic action in the treatment of MDD, and recommended parameters. We then focus on the data supporting its role for treatment of MDD.

BASIC PRINCIPLES OF TMS

TMS involves the application of intense (1.5 to 2.0 T), localized, pulsed magnetic fields to human tissue. These pulses are typically produced by electrical current traveling through coils of conductive material, such as copper wire. As predicted by Faraday’s law of physics, these electromagnetic fields induce electrical activity in peripheral and central nervous system tissues located in a perpendicular plane beneath the coil.⁴ When a TMS coil is placed on the head and the magnetic energy pulses are delivered with sufficient intensity, they penetrate through scalp and skull tissues to reach the brain cortex.⁵ Neuronal depolarization occurs, producing action potentials in targeted areas directly beneath the coil. TMS therapy, whether administered at a rate that is likely to be excitatory (5 to 10 Hz or higher) or inhibitory (≤ 1 Hz) to neuronal activity, is done with a series of pulses delivered together in a “train” of varying duration (eg, seconds to minutes), followed by a rest period during which no pulses are delivered.⁶ In addition to using it as a

tool to excite or inhibit regional activity in brain physiology experiments, TMS administered in a series of pulse trains comprises a “treatment session.” These sessions are repeated multiple days over a period of several weeks or months and have potential therapeutic applications for several neuropsychiatric disorders.⁷

MECHANISM OF ACTION

Similar to all other treatments for MDD, TMS’ therapeutic mechanism of action is unknown. Imaging studies report increased metabolism and blood flow with relatively “high frequency” TMS (HF-TMS; 10 or more pulses per second, or ≥ 10 Hz) over the left dorsolateral prefrontal cortex (DLPFC).⁸ Trans-synaptically, left HF-TMS activates other cortical and subcortical areas (in both the ipsilateral and contralateral hemispheres), including deeper neurocircuits implicated in the behavioral dysregulation characteristic of MDD (eg, sleep-wake cycle, appetite, energy level, ability to experience satisfaction in various activities). It has been proposed that 10-Hz DLPFC TMS works to entrain brain oscillatory rhythms in MDD patients, permitting the resetting of thalamocortical “pacemakers” in key regions where oscillations of electrical activity have become excessively synchronous. Entrainment with TMS may be a critical mechanism for restoring the intrinsic cerebral rhythms required for modulation of regional neuronal activity in response to the demands of one’s environment, as required for normal brain function.⁹

TMS FOR TREATMENT OF MAJOR DEPRESSION

Stimulation Parameters

The standard protocol associated with the U.S. Food and Drug Administration (FDA)-cleared, NeuroStar[®] TMS device (Neuronetics, Malvern, PA) for treatment of depression includes left DLPFC stimulation at 120% of motor threshold (MT), with magnetic field pulses de-

livered at 10 Hz in 4-second trains (40 pulses), followed by 26-second intertrain rest intervals (ITIs). With this cycle, 37.5 minutes are required for delivery of a total of 3,000 pulses in a single treatment session. Twenty or more, once-daily sessions are typically required to achieve clinical response with an acute treatment course, although some patients respond to fewer than 20 and others benefit from a longer course.^{10,11} Consistent with the protocol used in the pivotal clinical trial, a standard course of 30 TMS treatments over 6 weeks, followed by six additional taper treatments spaced over the final 3 weeks, is approved by most third-party payers who cover TMS.¹² Modifications (eg, increasing the number of pulses) of this regimen, however, are often undertaken to optimize the outcome.¹³

Pulsing TMS at a relatively low frequency (≤ 1 Hz) over the right DLPFC is also associated with relief from depressive symptoms, despite the fact that differential physiological effects appear related to TMS pulse frequency.¹⁴ The effect of “slow” TMS may be inhibitory rather than excitatory on neuronal activity in regions linked through cortical-subcortical networks. Often selected as a strategy for MDD patients with prominent anxiety, 1-Hz treatment on the right decreases regional cerebral blood flow to limbic regions such as amygdala.^{15,16} The convention of applying low-frequency (LF-) TMS specifically over the right hemisphere may have arisen from assumptions about cerebral laterality in depressed patients, but recent work suggests 1-Hz stimulation delivered over the left DLPFC may work equally as well for this population.¹⁷

A typical right-sided 1-Hz treatment session for MDD also involves stimulation over the DLPFC with magnetic field intensities up to 120% MT. Due to the lower risk for inadvertent seizure induction during 1-Hz pulsing, LF-TMS can safely be delivered in trains of relatively long durations, or alternatively as

TABLE 1.

Meta-Analyses Considering the Efficacy of TMS for Major Depression

Meta-Analysis	Studies (N)	Patients (N)	Outcome	Authors' Conclusions
McNamara et al. (2001) ²²	5	81	NNT = 2 to 3 (1.6 to 4.0)	TMS had demonstrable effects in treating major depression
Holtzheimer et al. (2001) ²³	12	264	ES = 0.81 (0.42 to 1.20)	TMS is statistically superior to sham stimulation for depression
Kozel & George (2002) ²⁴	12	230	ES = 0.53 (0.24 to 0.82)	TMS produced statistically significant effect sizes and measurable clinical improvement
Burt et al. (2002) ²⁵	23	432	ES = 0.62	Antidepressant effect is robust statistically; effect sizes are heterogenous
Martin et al. (2003) ²⁶	14	372	SMD = -0.35 (-0.66 to -0.04)	No strong evidence for benefit
Couturier (2005) ²⁷	6	91	Weighted mean difference = -1.1 (-4.5 to 2.3)	TMS is no different than sham treatment in major depression; the power within these studies to detect a difference was generally low
Hermann & Ebmeier (2006) ²⁸	33	877	ES = 0.71 (0.45 to 0.97)	TMS was more effective than sham, but variability was too great to take any single study design as paradigmatic
Gross et al. (2007) ²⁹	5	274	ES = -0.76 (-1.01 to 0.51)	Recent TMS trials had larger effect sizes compared with earlier trials
Lam et al. (2008) ³⁰	24	899	ES = 0.48 (0.28 to 0.69) Response: NNT = 6 Remission: NNT = 7	TMS is superior to sham in treatment of acute TRD
Schutter (2009) ³¹	30	1164	ES = 0.39 (0.25 to 0.54) ($P < 0.0001$)	HF-TMS over the left DLPFC is superior to sham
Slotema et al. (2010) ³²	34	1383	ES = 0.55 ($P < 0.001$)	HF-TMS superior to sham procedure
Berlim et al. (2013) ³³	8 6	263	Response: OR = 3.35 ($P < 0.007$), NNT = 5 Remission: OR = 4.76 ($P < 0.0001$), NNT = 5	Right LF-TMS is effective for major depression and similar to left HF-TMS
Berlim et al. (2014) ³⁴	29	1371	Response: OR = 3.3 ($P < 0.0001$), NNT = 6 Remission: OR = 3.3 ($P < 0.0001$), NNT = 8	Left HF-TMS superior to sham procedure

DLPFC = dorsolateral prefrontal cortex; ES = effect size; HF = high frequency; LF = low frequency; NNT = number needed to treat; OR = odds ratio; SMD = standard mean difference; TMS = transcranial magnetic stimulation; TRD = treatment-resistant depression.

a single continuous train of pulses given without any pauses. Published protocols for 1-Hz stimulation describe a wide range of total pulses per session.¹⁴ The largest MDD sample to receive 1-Hz TMS to date was treated with 1,800 pulses per session, at 120% MT intensity.¹¹ Potential benefits of LF-TMS may include better tolerability and less risk for seizures compared with HF-TMS.¹⁸ Although some data support sequencing right LF-TMS with left HF-TMS in the

same session, a recent, sham-controlled trial did not confirm better efficacy of sequenced/bilateral TMS in comparison to left HF-TMS alone.¹⁹

Currently, the largest database for the therapeutic use of TMS describes treatment of patients with unipolar MDD. Most studies included patients who were moderately to severely depressed and also treatment-resistant or intolerant to standard antidepressant medications. Early, controlled studies found little to

only modest differences between active and sham TMS. Later trials, however, consistently reported a significant and clinically relevant benefit favoring active TMS over the sham procedure.²⁰ This discrepancy is related to several factors, including the use in later trials of larger samples, more aggressive TMS dosing parameters, improved methods for targeting and coil placement, and delivery of a greater number of pulses per treatment session and total sessions

TABLE 2.

Important Characteristics of Recent Large Controlled TMS Studies for Major Depression

Study	N ^a	Gender Breakdown	Treatment Resistance	TMS Procedure	Sham Procedure and Coil Placement	Primary Outcome
O'Reardon et al. (2007) ¹²	301	Active: 69 men/86 women Sham: 2 men/74 women	1 to 4 failed adequate AD trials or intolerant to 4 trials (<i>M</i> = 1.5 failed trials)	HF-TMS (10 Hz) to left DLPFC 4-sec train; 26-sec ITI 3,000 pulses/session—up to 30 sessions (90,000 pulses) Limited rescue medications	Metal insert in coil to block magnetic field 5-cm rule for coil placement	MADRS change score at week 4
George et al. (2010) ³⁵	190	Active: 4 men/58 women Sham: 48 men/50 women	1 to 4 failed adequate AD trials or intolerant to ≥3 trials (<i>M</i> = 1.5 failed trials)	HF-TMS (10 Hz) to left DLPFC 4-sec train; 26-sec ITI 3,000 pulses/session—up to 30 sessions (90,000 pulses) Limited rescue medications	Metal insert in coil to block magnetic field Scalp electrodes to deliver matched somatosensory sensations 5-cm rule for coil placement with MRI-guided adjustment	Proportion of remitters at week 6 based on the HDRS-24
Brainsway Deep TMS System ³⁶	233	Active: 108 ^b Sham: 121 ^b	1 to 4 failed adequate AD trials or intolerant to ≥2 trials	HF-TMS (18 Hz) to medial and lateral PFC 120% MT 1,980 pulses/session—total of 20 sessions (29,600 pulses) DTMS H-coil	Electric currents traveling opposite directions in coil's double wires produce negligible magnetic field Broad field/large coil windings enclosed in helmet	HDRS-21 change score at week 4

AD = antidepressant; DLPFC = dorsolateral prefrontal cortex; DTMS = deep transcranial magnetic stimulation; HDRS = Hamilton Depression Rating Scale; HF = high frequency; ITI = intertrain rest intervals; MADRS = Montgomery-Åsberg Depression Rating Scale; MT = motor threshold; MRI = magnetic resonance imaging; PFC = prefrontal cortex; TMS = transcranial magnetic stimulation.

^a Number in intent-to-treat sample.

^b Breakdown by gender not available in published documents.

per course of therapy. Earlier work reflects a more conservative application of pulsed magnetic fields to human brain as safety data were gradually emerging, whereas more recent trials incorporating greater “doses” of TMS (likely, with better penetration to key anatomical structures) were associated with more robust antidepressant effects. In addition, safety and tolerability issues using these more aggressive TMS parameters were clarified and generally found to be less problematic than medications or electroconvulsive therapy (ECT).²¹ Studies involving TMS for depression can be divided into:

- Randomized, controlled trials (RCTs) of TMS as monotherapy or adjunctive therapy versus a sham procedure.
- Studies of TMS versus ECT.
- Naturalistic, observational outcome studies that consider the acute and sustained benefits of TMS.

Randomized, Sham-Controlled, TMS Trials for Major Depression

There are now more than 35 randomized, double-blind, sham-controlled TMS trials for depression reported in the literature. Owing to the requirement for a safe and conservative approach to the development of a novel modality for

therapeutic brain manipulation (ie, using energy fields produced by investigational devices), the trajectory of TMS research over time has been incremental and reflects implementation of trial designs that prioritized the safety of depressed patients. Notable limitations characterize some of the published controlled trials, including modest sample sizes, inclusion of patients on stable concurrent pharmacotherapy, use of suboptimal sham procedures, and inclusion of both unipolar and bipolar depressed patients. Further, relatively few captured follow-up data regarding maintenance of effect after completion of an acute treatment

Copyright 2014 SLACK Inc.

series. Despite these limitations, several meta-analyses concluded that HF-TMS over the left DLPFC demonstrates a statistical and clinically relevant acute benefit compared with a sham procedure (**Table 1**).²²⁻³⁴

The most recent meta-analysis included 29 RCTs involving 1,371 patients with MDD.³⁴ After an average of 13 TMS sessions (range = 10 to 30), response and remission rates were 29.3% and 18.6%, respectively, with active TMS. By contrast, those rates were 10.4% and 5%, respectively, with the sham procedure. The pooled odds ratio (OR) for both response and remission rates was 3.3 ($P < 0.0001$) and the number needed to treat (NNT) was 6 and 8, respectively. Of note, the authors reported no difference when TMS was used as a monotherapy or augmentation approach; when used in mixed samples involving both unipolar and bipolar depressed patients; or when delivered as either left HF-TMS or right LF-TMS. Further, dropout rates were similar between the active and sham arms (ie, 7.5% versus 7.6%).

The two largest MDD published studies to date included 491 patients ($n = 301$ and $n = 190$, respectively) randomized to either active or sham TMS.^{12,35} These two trials used less conservative stimulation parameters for acute treatment of MDD with left HF-TMS (**Table 2**). Both studies entered only treatment-resistant, nonmedicated, nonpsychotic, unipolar major depressive patients and used the same device, the first of its kind to receive FDA clearance for treatment of depression. Critical parameters included stimulation over the left DLPFC with pulse intensity of 120% MT, at a frequency of 10 Hz (4-second pulse train and 26-second ITI) for up to 30 sessions (90,000 pulses) delivered once daily over 6 weeks, followed by six taper treatments during weeks 7 to 9. Relative to earlier trials, greater attention was given to blinding in both studies, including use of more appropriate sham coils.

The George et al.³⁵ study optimized sham treatment through use of an electrical stimulator that delivered weak, pulsed currents to surface electrodes on each subject's face and head during TMS sessions to mask the sensations produced by the active TMS device. The primary outcomes from this second, large, sham-controlled trial using stan-

for 4 weeks. The acute phase was followed by a maintenance phase in which subjects were treated twice weekly for another 12 weeks. Acute phase DTMS therapy was associated with a 6.39-point decrease on the 21-item HDRS, compared with 3.11 points in the sham group ($P < 0.008$). These results were corroborated by statistically significant improvements in the Clinical Global Impression of Improvement scores at week 5, which were also maintained through week 16. Similar to clinical trials conducted with the predicate TMS device, no negative cognitive effects were associated with the Brainsway DTMS treatment. The main side effects of active DTMS included jaw and stimulation site pain. One seizure was reported.

Remission rates were approximately 15% for active and 5% for sham TMS in both trials based on the 24-item Hamilton Depression Rating Scale scores.

dard depression assessments confirmed the findings reported by O'Reardon et al.¹² For example, remission rates were approximately 15% for active and 5% for sham TMS in both trials based on the 24-item Hamilton Depression Rating Scale (HDRS-24) scores.

Recently, a large double-blind, multicenter RCT ($n = 233$ intent-to-treat; $n = 181$ efficacy sample) was conducted by the manufacturers of a new TMS device thought to deliver stimulating pulses which penetrate more deeply into the cortex.³⁶ In contrast to the iron-core coil used by the NeuroStar TMS device, an "H-coil" with air core and complex windings placed over a larger surface area of medial and lateral prefrontal cortex characterizes the Brainsway® (Jerusalem, Israel) "deep TMS" (DTMS) approach. This coil received FDA clearance for treatment of adults with MDD in January 2013.³⁶ In the double-blind, sham-controlled TMS trial conducted with the H-coil and Magstim Rapid® stimulators (Whitland, Wales, UK), TMS sessions (ie, 2-second trains, 20-second ITIs, at 18 Hz, 120% MT, 55 trains, 1,980 pulses per session, session duration of 20.2 minutes) were delivered 5 days per week

Randomized Trials of TMS versus ECT for Major Depression

The potential role of TMS relative to ECT considers different scenarios. For example, there are preliminary data that TMS may be sequenced with ECT to achieve similar benefit but minimize adverse cognitive effects, or that TMS may be used as a maintenance strategy after a successful acute course of ECT.³⁷⁻³⁹ The largest database, however, considers whether TMS may be an alternative to ECT for an acute MDD episode. This is of importance given the adverse effects associated with ECT are typically absent with TMS. Further, the pending decision by the FDA for categorizing ECT devices may limit its use in the future.

There are currently nine published trials (seven randomized, two open-label) of left HF-TMS and one trial of right LF-TMS versus ECT in the literature (**Table 3**).⁴⁰⁻⁵⁰ All involved depressed patients who were deemed appropriate candidates for ECT. Each of these trials, however, has significant limitations. These include small samples, nonblinded assessments, and no sham procedure. In most studies, the total number of TMS sessions was low and

TABLE 3.

Outcome in Depressed Patients Randomized or Assigned to TMS or ECT

Randomized Studies	Outcome		Comments
	ECT (%)	TMS (%)	
Grunhaus et al. (2000) ⁴⁰	16 of 20 (80%)	9 of 20 (41%)	Response rate: HDRS-17 ($\geq 50\%$); GAS (≥ 60) TMS comparable to UND/BL ECT in nonpsychotic major depression
Pridmore et al. (2000) ⁴¹	11 of 16 (69%)	11 of 16 (69%)	Remission rate: HDRS-17 (≤ 8) UND ECT
Janicak et al. (2002; 2005) ^{42,43}	6 of 14 (43%)	7 of 17 (41%)	Response rate: HDRS-24 ($\geq 50\%$; ≤ 8) BL ECT
Grunhaus et al. (2003) ⁴⁴	12 of 20 (60%) 6 of 20 (30%)	11 of 20 (55%) 6 of 20 (30%)	Response rate: HDRS $\geq 50\%$; < 10 ; GAS ≥ 60) Remission rate: HDRS ≤ 8) HDRS-17 UND ECT
Rosa et al. (2006) ⁴⁵	6 of 15 (40%)	1 of 20 (50%)	Response rate: HDRS-17 ($\geq 50\%$) UND/BL ECT
Eranti et al. (2007) ⁴⁶	13 of 22 (59%)	4 of 24 (17%)	Remission rate: HDRS-17 (≤ 8) UND/BL ECT
Keshtkar et al. (2011) ⁴⁷	68% improvement from baseline ($n = 40$)	29% improvement from baseline ($n = 33$)	HDRS-21 HF-TMS (total pulses = 4,080) BL ECT
Hansen et al. (2011) ⁴⁸	26% higher rate of partial remission with ECT ($P < 0.04$)		HDRS-17 LF-TMS ($n = 30$) UND ECT ($n = 30$)
Nonrandomized Studies			
O'Connor et al. (2003) ⁴⁹	62% mean improvement from baseline ($n = 14$)	10% mean improvement from baseline ($n = 14$)	HDRS-17 UND ECT
Schulze-Rauschenbach et al. (2005) ⁵⁰	6 of 14 (46%)	7 of 16 (44%)	Response rate: HDRS-17 ($\geq 50\%$) UND ECT

BL = bilateral; ECT = electroconvulsive therapy; HDRS = Hamilton Depression Rating Scale; HF = high frequency; GAS = Global Assessment Scale; LF = low frequency; TMS = transcranial magnetic stimulation; UND = unilateral, nondominant.

would be considered subtherapeutic by today's standards. Further, most did not measure durability of effect beyond the acute treatment phase. With these limitations in mind, one recent meta-analysis of seven randomized left HF-TMS trials concluded that ECT was superior to TMS, with 50% and 30% of patients achieving remission, respectively.⁵¹ Another meta-analysis of data from nine trials also found ECT to be superior to TMS, particularly for patients with psychotic depression.⁵² Among nonpsy-

chotic patients, however, both HF-TMS and LF-TMS were as effective as ECT.

Although TMS therapy as it is currently delivered should not replace ECT for all MDD patients, the two treatment modalities may be complementary with either preferable for specific subgroups of depressed patients. The ideal study design for investigating the comparative efficacy of TMS and ECT requires a larger sample, better baseline matching, longer follow-up period, and a more intensive treatment protocol than used in

past studies. As pointed out by another group who conducted a meta-analysis of these data, standardization of TMS stimulus parameters may play an important role in clarifying its efficacy relative to ECT.⁵³ The ongoing development of new TMS coils and the application of therapy with different stimulation parameters at alternate sites (eg, DMPFC, ventromedial prefrontal cortex) creates additional challenges for conducting properly controlled investigations to compare the relative effectiveness of TMS with ECT.

Copyright 2014 SLACK Inc.

DURABILITY OF ACUTE TMS ANTIDEPRESSANT EFFECTS

Although numerous RCTs are assessing the acute efficacy of TMS for MDD, results from controlled trials specifically describing its durability of effect have yet to be published. A number of case series and open studies, however, rendered consistent findings, particularly when “booster” treatments with TMS are available to “rescue” patients showing evidence of clinical deterioration. In one study, 59 treatment-resistant depressed (TRD) patients who responded to an acute course of TMS were followed for 20 weeks (37 receiving maintenance TMS and 22 no additional TMS treatments).⁵⁴ At study endpoint, there was a statistically significant difference in relapse rates favoring the maintenance TMS group (ie, 38% versus 82%; hazard ratio = 0.288; confidence interval [0.124, 0.669]; $P < 0.004$). Another trial ($n = 35$) found that prophylactic “cluster” TMS sessions (ie, five treatments delivered over 2 days each month) given to patients who had responded to two prior courses of TMS (initial therapy and subsequent retreatment delivered in the face of depressive relapse) substantially increased the period of wellness and delayed the onset of future relapse.⁵⁵ A retrospective, cohort study followed 42 patients who met response or remission criteria after an acute trial of TMS for a major depressive episode (either unipolar or bipolar).⁵⁶ The authors reported that 62% maintained their acute clinical benefit over 6 months with adjunctive maintenance TMS. In a third trial, after achieving remission in the randomized controlled phase, durability of clinical benefit was assessed over 3 months following a protocol-specified TMS taper and either continued pharmacotherapy or naturalistic follow up.⁵⁷ At the end of 3 months, 29 of 50 (58%) continued in remission, 2 of 50 (4%) were partial responders, and 1 of 50 (2%) had relapsed. As a follow up to the Neuronetics’ pivotal TMS study, a group of 99 pa-

tients with MDD who met criteria for at least partial response (ie, $\geq 25\%$ decrease in HDRS-17 baseline score) after an acute course of TMS were transitioned to a single maintenance antidepressant medication and followed for 6 months.⁵⁸ Ten of 99 (13%) patients relapsed. Thirty-eight of 99 (38%) met prespecified criteria for symptom worsening and began retreat-

An important issue is whether symptomatic improvement from TMS translates into higher functioning and a better quality of life.

ment with TMS. Of these, 32 of 38 (84%) re-achieved symptomatic benefit. In a 6-month, retrospective naturalistic study ($n = 204$), younger age and increased number of TMS sessions were associated with longer periods of remission.⁵⁹ In an open-label, prospective study, 16 unmedicated TRD patients initially responded to an acute course of TMS.⁶⁰ Over 4 years, this group experienced a total of 64 relapses with approximately half sustaining a clinically significant response to repeated courses of TMS. The duration of benefit from each course of TMS persisted for an average of nearly 5 months. Finally, after acute response, 10 depressed adults were provided maintenance TMS treatments with a session frequency of 1 to 2 per week, ranging from 6 months to 6 years. Seven of 10 (70%) experienced sustained marked or moderate benefit without any serious adverse events.⁶¹

Three other ongoing studies are also relevant. In conversation with D.L. Dunner, MD (March 2014), a 12-month, naturalistic outcome study involving 257 patients who had responded to acute TMS therapy in “real-life practice settings” was recently completed; the results are currently in press. In a second ongoing,

randomized maintenance-of-effect study, unmedicated patients who responded to an acute course of TMS are receiving monthly follow-up assessments for 1 year. In addition, one group is randomized to receive a single booster TMS session each month. Either group can also receive re-introduction TMS if clinical worsening occurs. The results of this trial are also pending per conversation with D.G. Brock, MD (March 2014). Finally, a Chinese study is in progress that acutely stabilizes patients with MDD using venlafaxine and then randomizes them to three different maintenance strategies (ie, venlafaxine only; venlafaxine plus active TMS; venlafaxine plus sham TMS) over 12 months.⁶²

The data reported thus far add to the evidence that individuals who initially benefitted from an acute course of TMS therapy are able to respond to TMS retreatment delivered in the context of clinical deterioration or episode recurrence at some point after completion of the acute treatment series. The ideal TMS maintenance schedule for supporting optimal durability of acute treatment response, however, has yet to be defined.

FUTURE DIRECTIONS

Although much progress has been made toward optimizing left HF-TMS as a treatment option for patients with MDD, the beneficial effects of this novel, noninvasive brain stimulation treatment can still be enhanced. Promising new strategies to improve efficacy of TMS will require verification from naturalistic trials. An important issue is whether symptomatic improvement from TMS translates into higher functioning and a better quality of life. In this context, recent outcome studies support the use of TMS for MDD.^{56,63-65} Additional strategies, which may enhance the efficacy of TMS, include optimized coil placement, delivery of stimulation over alternate brain targets, further refinement of treatment parameters, deeper penetration of TMS electromagnetic fields into the cor-

Copyright 2014 SLACK Inc.

tex, and development of biomarkers to predict responsivity (eg, brain-derived neurotrophic factor; functional magnetic resonance imaging).⁶⁶⁻⁶⁸

CONCLUSION

The results of studies with HF-TMS stimulation over the left DLPFC support a clinically relevant, acute antidepressant benefit with the first FDA-cleared TMS device for MDD when compared with a sham procedure. Preliminary data suggest that next-generation devices with alternative coil designs will be as good or better at bringing about relief of depressive symptoms. In preliminary trials, TMS' durability of effect after acute response appears substantive and is associated with improvement in functioning and quality of life. In support of the clinical utility of TMS for MDD, groups such as the New England Comparative Effectiveness Public Advisory Council have reviewed the peer-reviewed published evidence for TMS in TRD, concluded TMS was as good or better than "treatment as usual," and that TMS represents a reasonable value.⁶⁹

REFERENCES

- Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. *PLoS Med.* 2013;10(11):e1001547.
- Olchanski N, McInnis Myers M, Halseth M, et al. The economic burden of treatment-resistant depression. *Clin Ther.* 2013;35(4):512-522.
- Insel TR, Wang PS. The STAR*D trial: revealing the need for better treatments. *Psychiatr Serv.* 2009;60(11):1466-1467.
- Faraday M, Day P. *The Philosopher's Tree: A Selection of Michael Faraday's Writings*. Boca Raton, FL: CRC Press; 1993:71.
- Post A, Keck ME. Transcranial magnetic stimulation as a therapeutic tool in psychiatry: what do we know about the neurobiological mechanisms? *J Psychiatr Res.* 2001;35(4):193-215.
- Wassermann EM, Grafman J, Berry C, et al. Use and safety of a new repetitive transcranial magnetic stimulator. *Electroencephalogr Clin Neurophysiol.* 1996;101(5):412-417.
- Rado JT, Dowd SM, Janicak PG. The emerging role of transcranial magnetic stimulation (TMS) for treatment of psychiatric disorders. *New Dir Psychiatry.* 2008;28:315-331.
- Padberg F, George MS. Repetitive transcranial magnetic stimulation of the prefrontal cortex in depression. *Exp Neurol.* 2009;219(1):2-13.
- Leuchter AF, Cook IA, Jin Y, Phillips B. The relationship between brain oscillatory activity and therapeutic effectiveness of transcranial magnetic stimulation in the treatment of major depressive disorder. *Front Hum Neurosci.* 2013;7:37.
- Janicak PG, Dowd SM, Rado JT, Welch MJ. The re-emerging role of therapeutic neuromodulation. *Curr Psychiatry.* 2010;9(11):66-74.
- McDonald WM, Durkalski V, Ball ER, et al. Improving the antidepressant efficacy of transcranial magnetic stimulation: maximizing the number of stimulations and treatment location in treatment-resistant depression. *Depress Anxiety.* 2011;28(11):973-980.
- O'Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. *Biol Psychiatry.* 2007;62(11):1208-1216.
- Holtzheimer PE, McDonald WM, Muftic M, et al. Accelerated repetitive transcranial magnetic stimulation for treatment-resistant depression. *Depress Anxiety.* 2010;27(10):960-963.
- Berlim MT, Van den Eynde F, Daskalakis ZJ. Clinically meaningful efficacy and acceptability of low-frequency repetitive transcranial magnetic stimulation (rTMS) for treating primary major depression: a meta-analysis of randomized, double-blind and sham-controlled trials. *Neuropsychopharmacology.* 2013;38:543-551.
- Mantovani A, Aly M, Dagan Y, Allart A, Lisanby SH. Randomized sham controlled trial of repetitive transcranial magnetic stimulation to the dorsolateral prefrontal cortex for the treatment of panic disorder with comorbid major depression. *J Affect Disord.* 2013;144(1-2):153-159.
- Speer AM, Kimbrell TA, Wassermann EM, et al. Opposite effects of high and low frequency rTMS on regional brain activity in depressed patients. *Biol Psychiatry.* 2000;48(12):1133-1141.
- Speer AM, Wassermann EM, Benson BE, Herscovitch P, Post RM. Antidepressant efficacy of high and low frequency rTMS at 110% of motor threshold versus sham stimulation over left prefrontal cortex. *Brain Stimul.* 2014;7(1):36-41.
- Chen J, Zhou C, Wu B, et al. Left versus right repetitive transcranial magnetic stimulation in treating major depression: a meta-analysis of randomized controlled trials. *Psychiatry Res.* 2013;210:1260-1264.
- Fitzgerald PB, Hoy KE, Herring SE, et al. A double blind randomized trial of unilateral left and bilateral prefrontal cortex transcranial magnetic stimulation in treatment resistant major depression. *J Affect Disord.* 2012;139:193-198.
- Gross M, Nakamura L, Pascual-Leone A, Fregni F. Has repetitive transcranial magnetic stimulation (rTMS) treatment for depression improved? A systematic review and meta-analysis comparing the recent vs. the earlier rTMS studies. *Acta Psychiatr Scand.* 2007;116(3):165-173.
- Janicak PG, O'Reardon JP, Sampson SM, et al. Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. *J Clin Psychiatry.* 2008;69(2):222-232.
- McNamara B, Ray JL, Arthurs OJ, Boniface S. Transcranial magnetic stimulation for depression and other psychiatric disorders. *Psychol Med.* 2001;31(7):1141-1146.
- Holtzheimer PE III, Russo J, Avery DH. A meta-analysis of repetitive transcranial magnetic stimulation in the treatment of depression. *Psychopharmacol Bull.* 2001;35(4):149-169.
- Kozel FA, George MS. Meta-analysis of left prefrontal repetitive transcranial magnetic stimulation (rTMS) to treat depression. *J Psychiatr Pract.* 2002;8(5):270-275.
- Burt T, Lisanby SH, Sackeim HA. Neuropsychiatric applications of transcranial magnetic stimulation: a meta-analysis. *Int J Neuropsychopharmacol.* 2002;5:73-103.
- Martin JLR, Barbanj MJ, Schlaepfer TE, et al. Repetitive transcranial magnetic stimulation for the treatment of depression. Systematic review and meta-analysis. *Br J Psychiatry.* 2003;182:480-491.
- Couturier JL. Efficacy of rapid-rate repetitive transcranial magnetic stimulation in the treatment of depression: a systematic review and meta-analysis. *J Psychiatry Neurosci.* 2005;30(2):83-90.
- Hermann LL, Ebmeier KP. Factors modifying the efficacy of transcranial magnetic stimulation in the treatment of depression: a review. *J Clin Psychiatry.* 2006;67:1870-1876.
- Gross M, Nakamura L, Pascual-Leone A, Fregni F. Has repetitive transcranial magnetic stimulation (rTMS) treatment for depression improved? A systematic review and meta-analysis comparing the recent vs. the earlier rTMS studies. *Acta Psychiatr Scand.* 2007;116:165-173.
- Lam RW, Chan P, Wilkins-Ho M, Yatham LN. Repetitive transcranial magnetic stimulation for treatment-resistant depression: A systematic review and meta-analysis. *Can J Psychiatry.* 2008;53(9):621-631.
- Schutter DJLG. Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs: a meta-analysis. *Psychol Med.* 2009;39:65-75.
- Slotema CW, Blom JD, Hoek HW, Sommer IEC. Should we expand the toolbox of psychiatric treatment methods to include repetitive transcranial magnetic stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. *J Clin Psychiatry.* 2010;71(7):873-884.
- Berlim MT, Van den Eynde F, Daskalakis ZJ. Clinically meaningful efficacy and acceptability of low-frequency repetitive transcranial magnetic stimulation (rTMS) for treating primary major depression: a meta-analysis of randomized, double-blind and sham-controlled trials.

- Neuropsychopharmacology*. 2013;38:543-551.
34. Berlim MT, van den Eynde F, Tovar-Perdomo S, Daskalakis ZJ. Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. *Psychol Med*. 2014;44:225-239.
 35. George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. *Arch Gen Psychiatry*. 2010;67(5):507-516.
 36. Brainsway Deep TMS System. FDA 510(k) summary. 510(k) number K122288. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf12/K122288.pdf. Accessed March 5, 2014.
 37. Pridmore S. Substitution of rapid transcranial magnetic stimulation treatments for electroconvulsive therapy treatments in a course of electroconvulsive therapy. *Depress Anxiety*. 2000;12(3):118-1123.
 38. Cristancho MA, Helmer A, Connolly R, Cristancho P, O'Reardon JP. Transcranial magnetic stimulation maintenance as a substitute for maintenance electroconvulsive therapy: a case series. *J ECT*. 2013;29(2):106-108.
 39. Noda Y, Daskalakis ZJ, Ramos C, Blumberger DM. Repetitive transcranial magnetic stimulation to maintain treatment response to electroconvulsive therapy in depression: a case series. *Front Psychiatry*. 2013;23(4):73.
 40. Grunhaus L, Dannon PN, Schreiber S, et al. Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder: an open study. *Biol Psychiatry*. 2000;47:314-324.
 41. Pridmore S, Bruno R, Turnier-Shea Y, Reid P, Rybak M. Comparison of unlimited numbers of rapid transcranial magnetic stimulation (rTMS) and ECT treatment sessions in major depressive episode. *Int J Neuropsychopharmacol*. 2000;3:129-134.
 42. Janicak PG, Dowd SM, Martis B, et al. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: preliminary results of a randomized trial. *Biol Psychiatry*. 2002;51:659-667.
 43. Janicak PG, Dowd SM, Strong MJ, Alam D, Beedle D. The potential role of repetitive transcranial magnetic stimulation in treating severe depression. *Psychiatr Ann*. 2005;35(2):138-145.
 44. Grunhaus L, Schreiber S, Dolberg OT, Polak D, Dannon PN. A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression. *Biol Psychiatry*. 2003;53:324-331.
 45. Rosa MA, Gattaz WF, Pascual-Leone A, et al. Comparison of repetitive transcranial magnetic stimulation and electroconvulsive therapy in unipolar non-psychotic refractory depression: a randomized, single-blind study. *Int J Neuropsychopharmacol*. 2006;9(6):667-676.
 46. Eranti S, Mogg A, Pluck G, et al. A randomized, controlled trial with 6-month follow-up of repetitive transcranial magnetic stimulation and electroconvulsive therapy for severe depression. *Am J Psychiatry*. 2007;164:73-81.
 47. Keshtkar M, Ghanizadeh A, Firoozabadi A. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for the treatment of major depressive disorder, a randomized controlled clinical trial. *J ECT*. 2011;24(4):310-314.
 48. Hansen PE, Ravnkilde B, Videbech P, et al. Low-frequency repetitive transcranial magnetic stimulation inferior to electroconvulsive therapy in treating depression. *J ECT*. 2011;27(1):26-32.
 49. O'Connor M, Brennkmeier C, Morgan A, et al. Relative effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy on mood and memory: a neurocognitive risk-benefit analysis. *Cog Behav Neurol*. 2003;16:118-127.
 50. Schulze-Rauschenbach SC, Harms U, Schlaepfer TE, et al. Distinctive neurocognitive effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in major depression. *Br J Psychiatry*. 2005;186:410-416.
 51. Berlim et al, Van den Enynde F, Daskalakis ZJ. Efficacy and acceptability of high frequency repetitive transcranial magnetic stimulation (rTMS) versus electroconvulsive therapy (ECT) for major depression: a systematic review and meta-analysis of randomized trials. *Depress Anxiety*. 2013;30:614-623.
 52. Ren J, Li H, Palaniyappan L, et al. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: a systematic review and meta-analysis. *Prog Neuropsychopharmacol Biol Psychiatry*. 2014;51:181-189.
 53. Xie J, Chen J, Wei Q. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: a meta-analysis of stimulus parameter effects. *Neurol Res*. 2013;35(10):1084-1091.
 54. Richieri R, Guedj E, Michel P, et al. Maintenance transcranial magnetic stimulation reduces depression relapse: a propensity-adjusted analysis. *J Affect Disor*. 2013;151(1):129-135.
 55. Fitzgerald PB, Grace N, Hoy KE, Bailey M, Daskalakis ZJ. An open label trial of clustered maintenance rTMS for patients with refractory depression. *Brain Stimul*. 2013;6(3):292-297.
 56. Connolly KR, Helmer A, Cristancho MA, Cristancho R, O'Reardon JP. Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center. *J Clin Psychiatry*. 2012;73(4):e567-e573.
 57. Mantovani A, Pavlicova M, Avery D, et al. Long-term efficacy of repeated daily prefrontal transcranial magnetic stimulation (TMS) in treatment-resistant depression. *Depress Anxiety*. 2012;29(10):883-890.
 58. Janicak PG, Nahas Z, Lisanby SH, et al. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. *Brain Stimul*. 2010;3(4):187-199.
 59. Cohen RB, Boggio PS, Fregni F. Risk factor for relapse after remission with repetitive transcranial magnetic stimulation for the treatment of depression. *Depress Anxiety*. 2009;26(7):682-688.
 60. Demirtas-Tatlıdede A, Mechanic-Hamilton D, Press DZ, et al. An open-label, prospective study of repetitive transcranial magnetic stimulation (rTMS) in the long-term treatment of refractory depression: reproducibility and duration of the antidepressant effect in medication-free patients. *J Clin Psychiatry*. 2008;69(6):930-934.
 61. O'Reardon JP, Blummer KH, Peshek AD, Pradilla RR, Pimiento PC. Long-term maintenance therapy for major depressive disorder with rTMS. *J Clin Psychiatry*. 2005;66(12):1524-1528.
 62. Wang H, Xue Y, Chen Y, et al. Efficacy of repetitive transcranial magnetic stimulation in the prevention of relapse of depression: study protocol for a randomized controlled trial. *Trials*. 2013;14:338.
 63. Carpenter LL, Janicak PG, Aaronson St, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. *Depress Anxiety*. 2012;29:587-596.
 64. Solvason HB, Husain M, Fitzgerald PB, et al. Improvement in quality of life with left prefrontal transcranial magnetic stimulation in patients with pharmacoresistant major depression: acute and six month outcomes. *Brain Stimul*. 2014;7(2):219-225.
 65. Janicak PG, Dunner DL, Aaronson ST, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of quality of life outcome measures in clinical practice. *CNS Spectr*. 2013;18(6):322-332.
 66. Minichino A, Bersani FS, Capra E, et al. ECT, rTMS, and deep TMS in pharmacoresistant drug-free patients with unipolar depression: a comparative review. *Neuropsychiatr Dis Treat*. 2012;8:55-64.
 67. Downar J, Daskalakis ZJ. New targets for rTMS in depression: a review of convergent evidence. *Brain Stimul*. 2013;6:231-240.
 68. Fidalgo TM, Morales-Quezada L, Muzy GSC, et al. Biological markers in noninvasive brain stimulation trials in major depressive disorder: a systematic review. *J ECT*. 2014;30:47-61.
 69. Emond SK, Ollendorff DA, Colby JA, Reed SJ, Pearson SD. Evaluating the evidence on comparative effectiveness and value of management options for treatment-resistant depression. *Postgrad Med*. 2013;125(6):7-16.